Gilead Sciences – The Silver Bullet For NASH With Selonsertib And GS-9674 Combinations Treatment
- GS-9674 has good chances of posting positive trial results. Selonsertib is currently in the phase 3 study. Our analysis revealed that selonsertib is unlikely to deliver positive outcomes.
- However, the combinations of selonsertib and GS-9674 are seemingly the silver bullet for NASH fibrosis/cirrhosis.
- Unlikely the first mover to this lucrative market, Gilead’s NASH franchise will eventually take dominance over competitors.
- This is an abbreviated version of the in-depth nine-page-long Integrated BioSci Research available in advance to Integrated BioSci Investing subscribers.
Trading Analytics And Fundamental Analysis
On Dec. 15, 2017, the shares of Gilead Sciences (NASDAQ:GILD) increased $1.23 to $75.57 (for 1.65% profits). Based in Foster City, CA, the firm focuses on the innovation and commercialization of drugs that treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory disorders, and cardiovascular conditions.
At Integrated BioSci Investing, we’ve covered the lead molecule GS-9674 that we assess will post positive results for the phase 2 trial. By activating FXR, the said drug can potentially treat NASH as well as delivering numerous other regenerative benefits. Back in Nov. 2016, the ASK-1 inhibitor (selonsertib) showed favorable results for NASH in the phase 2 trial (and is being studied in the phase 3 study).